SCHEMBL29612689

SCHEMBL29612689

COc1ccc(CN2C(=O)CCC(n3c4ccccc4c4c(Br)ccnc43)C2=O)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 3/20 0.39
▸ KMT2A Q03164 3/20 0.39
▸ LMNA P02545 1/20 0.39
▸ P2RX4 Q99571 1/20 0.39
▸ DDB1 Q16531 1/20 0.38
▸ CRBN Q96SW2 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ BLM P54132 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ CTDSP1 Q9GZU7 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ ALDH1A1 P00352 2/20 0.36
▸ HCRTR1 O43613 2/20 0.36
▸ HCRTR2 O43614 2/20 0.36
▸ APAF1 O14727 1/20 0.36
▸ GAA P10253 1/20 0.36
▸ CASP3 P42574 1/20 0.36
▸ SENP8 Q96LD8 1/20 0.36
▸ SENP7 Q9BQF6 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21069615 1.00 MEN1 (0.39) MEN1KMT2ALMNAP2RX4DDB1
SCHEMBL21070398 0.87 MAPT (0.41) MEN1KMT2ALMNAP2RX4DDB1
SCHEMBL31664208 0.87 MAPT (0.41) MEN1KMT2ALMNAP2RX4DDB1
SCHEMBL23319581 0.87 MAPT (0.42) MEN1KMT2ALMNAP2RX4DDB1
SCHEMBL30036237 0.83 P2RX4 (0.49) MEN1KMT2ALMNAP2RX4BLM
SCHEMBL23319510 0.83 P2RX4 (0.49) MEN1KMT2ALMNAP2RX4BLM
SCHEMBL21070560 0.82 DDB1 (0.46) MEN1KMT2ALMNADDB1CRBN
SCHEMBL23319541 0.81 DDB1 (0.46) MEN1KMT2ALMNADDB1CRBN
SCHEMBL27085646 0.80 DDB1 (0.54) MEN1KMT2ALMNADDB1CRBN
SCHEMBL23319554 0.78 DDB1 (0.44) MEN1KMT2ALMNADDB1CRBN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250163042-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-05-22 — — US disclosed
US-11318205-B1 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2022-05-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250163042-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 MEN1 4055/4885KMT2A 445/4885LMNA 1656/4885
US-11318205-B1 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 MEN1 4055/4885KMT2A 445/4885LMNA 1656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback